Perspective on the genetics and diagnosis of congenital hyperinsulinism disorders

Journal of Clinical Endocrinology and Metabolism

Volumn 101, Issue 3, 2016, Pages 815-826

  Stanley, Charles A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAZOXIDE; FLUORO DIHYDROXYPHENYLALANINE F 18; OCTREOTIDE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; INSULIN;

ABCC8 GENE; ARTICLE; ASPHYXIA; BECKWITH WIEDEMANN SYNDROME; BIRTH WEIGHT; CLINICAL FEATURE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONGENITAL DISORDER OF GLYCOSYLATION; ENTERIC FEEDING; FLUID RETENTION; GCK GENE; GENE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC SCREENING; GLUD1 GENE; HADH1 GENE; HK1 GENE; HNF1A GENE; HNF4A GENE; HUMAN; HYPERAMMONEMIA SYNDROME; HYPERTRICHOSIS; INSULIN RELEASE; KABUKI MAKEUP SYNDROME; KCNJ11 GENE; MCT1 GENE; MOLECULAR GENETICS; NECROTIZING ENTEROCOLITIS; PANCREAS ISLET BETA CELL; PANCREAS RESECTION; PERSISTENT HYPERINSULINEMIC HYPOGLYCEMIA OF INFANCY; PGM1 GENE; PRIORITY JOURNAL; SIDE EFFECT; SIGNAL TRANSDUCTION; SMALL FOR DATE INFANT; TURNER SYNDROME; UCP2 GENE; CONGENITAL HYPERINSULINISM; GENETICS; NEWBORN; PHYSIOLOGY; SECRETION (PROCESS);

CONGENITAL HYPERINSULINISM; HUMANS; INFANT, NEWBORN; INSULIN; KATP CHANNELS;

EID: 84960845904     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-3651     Document Type: Article

References (98)

1. Hartmann AF, Jaudon JC. Hypoglycemia. J Pediatr. 1937;11:1-36.
2. McQuarrie I. Idiopathic spontaneously occurring hypoglycemia in infants; clinical significance of problem and treatment. AMA Am J Dis Child. 1954;87:399-428.
3. Stanley CA, Baker L. Hyperinsulinism in infants and children: diagnosis and therapy. Adv Pediatr. 1976;23:315-355.
4. Pagliara AS, Karl IE, Haymond M, Kipnis DM. Hypoglycemia in infancy and childhood. II. J Pediatr. 1973;82:558-577.
5. Steinkrauss L, Lipman TH, Hendell CD, Gerdes M, Thornton PS, Stanley CA. Effects of hypoglycemia on developmental outcome in children with congenital hyperinsulinism. J Pediatr Nurs. 2005;20: 109-118.
6. Lord K, Radcliffe J, Gallagher PR, Adzick NS, Stanley CA, De León DD. High risk of diabetes and neurobehavioral deficits in individuals with surgically treated hyperinsulinism. J Clin Endocrinol Metab. 2015;100:4133-4139.
7. Cochrane WA, Payne WW, Simpkiss MJ, Woolf LI. Familial hypoglycemia precipitated by amino acids. J Clin Invest. 1956;35:411-422.
8. Yalow RS, Berson SA. Immunoassay of endogenous plasma insulin in man. J Clin Invest. 1960;39:1157-1175.
9. Drash A, Wolff F. Drug therapy in leucine-sensitive hypoglycemia. Metabolism. 1964;13:487-492.
10. Yakovac WC, Baker L, Hummeler K. β Cell nesidioblastosis in idiopathic hypoglycemia of infancy. J Pediatr. 1971;79:226-231.
11. Rahier J, Wallon J, Henquin JC. Cell populations in the endocrine pancreas of human neonates and infants. Diabetologia. 1981;20: 540-546.
12. Palladino AA, Stanley CA. Nesidioblastosis no longer! It's all about genetics. J Clin Endocrinol Metab. 2011;96:617-619.
13. Aguilar-Bryan L, Nichols CG, Wechsler SW, et al. Cloning of the β cell high-affinity sulfonylurea receptor: a regulator of insulin secretion. Science. 1995;268:423-426.
14. Thomas PM, Cote GJ, Wohllk N, et al. Mutations in the sulfonylurea receptor gene in familial persistent hyperinsulinemic hypoglycemia of infancy. Science. 1995;268:426-429.
15. Nestorowicz A, Wilson BA, Schoor KP, et al. Mutations in the su-lonylurea receptor gene are associated with familial hyperinsulinism in Ashkenazi Jews. Hum Mol Genet. 1996;5:1813-1822.
16. Thomas P, Ye Y, Lightner E. Mutation of the pancreatic islet inward rectifier Kir6.2 also leads to familial persistent hyperinsulinemic hypoglycemia of infancy. Hum Mol Genet. 1996;5:1809-1812.
17. Nestorowicz A, Inagaki N, Gonoi T, et al. A nonsense mutation in the inward rectifier potassium channel gene, Kir6.2, is associated with familial hyperinsulinism. Diabetes. 1997;46:1743-1748.
18. Sayed S, Langdon DR, Odili S, et al. Extremes of clinical and enzymatic phenotypes in children with hyperinsulinism caused by glu-cokinase activating mutations. Diabetes. 2009;58:1419-1427.
19. Bruining GJ. Recent advances in hyperinsulinism and the pathogenesis of diabetes mellitus. Curr Opin Pediatr. 1990;2:758-765.
20. Mathew PM, Young JM, Abu-Osba YK, et al. Persistent neonatal hyperinsulinism. Clin Pediatr (Phila). 1988;27:148-151.
21. Glaser B, Blech I, Krakinovsky Y, et al. ABCC8 mutation allele frequency in the Ashkenazi Jewish population and risk of focal hyperinsulinemic hypoglycemia. Genet Med. 2011;13:891-894.
22. Huang T, Kelly A, Becker SA, Cohen MS, Stanley CA. Hypertrophic cardiomyopathy in neonates with congenital hyperinsulinism. Arch Dis Child Fetal Neonatal Ed. 2013;98:F351-F354.
23. Stanley CA, Rozance PJ, Thornton PS, et al. Re-evaluating "transitional neonatal hypoglycemia": mechanism and implications for management. J Pediatr. 2015;166:1520-1525.e1.
24. Pinney SE, Mac Mullen C, Becker S, et al. Clinical characteristics and biochemical mechanisms of congenital hyperinsulinism associated with dominant KATP channel mutations. J Clin Invest. 2008;118: 2877-2886.
25. Stanley CA, Baker L. Hyperinsulinism in infancy: diagnosis by demonstration of abnormal response to fasting hypoglycemia. Pediatrics. 1976;57:702-711.
26. Finegold DN, Stanley CA, Baker L. Glycemic response to glucagon during fasting hypoglycemia: an aid in the diagnosis of hyperinsulinism. J Pediatr. 1980;96:257-259.
27. Ferrara C, Patel P, Becker S, Stanley CA, Kelly A. Biomarkers of insulin for the diagnosis of hyperinsulinemic hypoglycemia in infants and children. J Pediatr. 2016;168:212-219.
28. Sayed S, Matschinsky FM, Stanley CA. Hyperinsulinism due to activating mutations of glucokinase. In: De Léon DD, Stanley CA, eds. Monogenic Hyperinsulinemic Hypoglycemia Disorders. Geneva, Switzerland: Karger; 2012:146-157.
29. Snider KE, Becker S, Boyajian L, et al. Genotype and phenotype correlations in 417 children with congenital hyperinsulinism. J Clin Endocrinol Metab. 2013;98:E355-E363.
30. Yoshida K, Kawai M, Marumo C, et al. High prevalence of severe circulatory complications with diazoxide in premature infants. Neonatology. 2014;105:166-171.
31. Thornton PS, Alter CA, Katz LE, Baker L, Stanley CA. Short-and long-term use of octreotide in the treatment of congenital hyperinsulinism. J Pediatr. 1993;123:637-643.
32. Laje P, Halaby L, Adzick NS, Stanley CA. Necrotizing enterocolitis in neonates receiving octreotide for the management of congenital hyperinsulinism. Pediatr Diabetes. 2010;11:142-147.
33. Lovvorn HN 3rd, Nance ML, Ferry RJ Jr, et al. Congenital hyperinsulinism and the surgeon: lessons learned over 35 years. J Pediatr Surg. 1999;34:786-792; discussion 792-793.
34. Adzick NS, Thornton PS, Stanley CA, Kaye RD, Ruchelli E. A mul-tidisciplinary approach to the focal form of congenital hyperinsulinism leads to successful treatment by partial pancreatectomy. J Pediatr Surg. 2004;39:270-275.
35. Hardy OT, Hernandez-Pampaloni M, Saffer JR, et al. Diagnosis and localization of focal congenital hyperinsulinism by 18F-fluorodopa PET scan. J Pediatr. 2007;150:140-145.
36. Kelly A, Ng D, Ferry RJ Jr, et al. Acute insulin responses to leucine in children with the hyperinsulinism/hyperammonemia syndrome. J Clin Endocrinol Metab. 2001;86:3724-3728.
37. De León DD, Li C, Delson MI, Matschinsky FM, Stanley CA, Stoffers DA. Exendin-(9-39) corrects fasting hypoglycemia in SUR-1-/-mice by lowering cAMP in pancreatic β-cells and inhibiting insulin secretion. J Biol Chem. 2008;283:25786-25793.
38. Shyng SL, Ferrigni T, Shepard JB, et al. Functional analyses of novel mutations in the sulfonylurea receptor 1 associated with persistent hyperinsulinemic hypoglycemia of infancy. Diabetes. 1998;47: 1145-1151.
39. Yan FF, Lin YW, Mac Mullen C, Ganguly A, Stanley CA, Shyng SL. Congenital hyperinsulinism associated ABCC8 mutations that cause defective trafficking of ATP-sensitive K+ channels: identification and rescue. Diabetes. 2007;56:2339-2348.
40. Macmullen CM, Zhou Q, Snider KE, et al. Diazoxide-unresponsive congenital hyperinsulinism in children with dominant mutations of the β-cell sulfonylurea receptor SUR1. Diabetes. 2011;60:1797-1804.
41. Glaser B, Ryan F, Donath M, et al. Hyperinsulinism caused by paternal-specific inheritance of a recessive mutation in the sulfony-lurea-receptor gene. Diabetes. 1999;48:1652-1657.
42. Laje P, Stanley CA, Palladino AA, Becker SA, Adzick NS. Pancreatic head resection and Roux-en-Y pancreaticojejunostomy for the treatment of the focal form of congenital hyperinsulinism. J Pediatr Surg. 2012;47:130-135.
43. Suchi M, Thornton PS, Adzick NS, et al. Congenital hyperinsulinism: intraoperative biopsy interpretation can direct the extent of pancreatectomy. Am J Surg Pathol. 2004;28:1326-1335.
44. Hardy OT, Hernandez-Pampaloni M, Saffer JR, et al. Accuracy of [18F]Fluorodopa positron emission tomography for diagnosing and localizing focal congenital hyperinsulinism. J Clin Endocrinol Metab. 2007;92:4706-4711.
45. Laje P, States LJ, Zhuang H, et al. Accuracy of PET/CT scan in the diagnosis of the focal form of congenital hyperinsulinism. J Pediatr Surg. 2013;48:388-393.
46. Otonkoski T, Näntö-Salonen K, Seppänen M, et al. Noninvasive diagnosis of focal hyperinsulinism of infancy with [18F]-DOPA positron emission tomography. Diabetes. 2006;55:13-18.
47. Stanley CA, Lieu YK, Hsu BY, et al. Hyperinsulinism and hyperammonemia in infants with regulatory mutations of the glutamate dehydrogenase gene. N Engl J Med. 1998;338:1352-1357.
48. Mac Mullen C, Fang J, Hsu BY, et al. Hyperinsulinism/hyperammonemia syndrome in children with regulatory mutations in the inhibitory guanosine triphosphate-binding domain of glutamate dehydrogenase. J Clin Endocrinol Metab. 2001;86:1782-1787.
49. Fang J, Hsu BY, Mac Mullen CM, Poncz M, Smith TJ, Stanley CA. Expression, purification and characterization of human glutamate dehydrogenase (GDH) allosteric regulatory mutations. Biochem J. 2002;363:81-87.
50. Li C, Matter A, Kelly A, et al. Effects of a GTP-insensitive mutation of glutamate dehydrogenase on insulin secretion in transgenic mice. J Biol Chem. 2006;281:15064-15072.
51. Treberg JR, Clow KA, Greene KA, Brosnan ME, Brosnan JT. Systemic activation of glutamate dehydrogenase increases renal ammo-niagenesis: implications for the hyperinsulinism/hyperammonemia syndrome. Am J Physiol Endocrinol Metab. 2010;298:E1219-E1225.
52. Raizen DM, Brooks-Kayal A, Steinkrauss L, Tennekoon GI, Stanley CA, Kelly A. Central nervous system hyperexcitability associated with glutamate dehydrogenase gain of function mutations. J Pediatr. 2005;146:388-394.
53. Glaser B, Kesavan P, Heyman M, et al. Familial hyperinsulinism caused by an activating glucokinase mutation. N Engl J Med. 1998; 338:226-230.
54. Clayton PT, Eaton S, Aynsley-Green A, et al. Hyperinsulinism in short-chain L-3-hydroxyacyl-Co A dehydrogenase deficiency reveals the importance of β-oxidation in insulin secretion. J Clin Invest. 2001;108:457-465.
55. Molven A, Matre GE, Duran M, et al. Familial hyperinsulinemic hypoglycemia caused by a defect in the SCHAD enzyme of mitochondrial fatty acid oxidation. Diabetes. 2004;53:221-227.
56. Li C, Chen P, Palladino A, et al. Mechanism of hyperinsulinism in short-chain 3-hydroxyacyl-Co A dehydrogenase deficiency involves activation of glutamate dehydrogenase. J Biol Chem. 2010;285: 31806-31818.
57. González-Barroso MM, Giurgea I, Bouillaud F, et al. Mutations in UCP2 in congenital hyperinsulinism reveal a role for regulation of insulin secretion. PLoS One. 2008;3:e3850.
58. Vozza A, Parisi G, De Leonardis F, et al. UCP2 transports C4 metabolites out of mitochondria, regulating glucose and glutamine oxidation. Proc Natl Acad Sci USA. 2014;111:960-965.
59. Pearson ER, Boj SF, Steele AM, et al. Macrosomia and hyperinsuli-naemic hypoglycaemia in patients with heterozygous mutations in the HNF4A gene. PLoS Med. 2007;4:e118.
60. Stanescu DE, Hughes N, Kaplan B, Stanley CA, De León DD. Novel presentations of congenital hyperinsulinism due to mutations in the MODY genes: HNF1A and HNF4A. J Clin Endocrinol Metab. 2012;97:E2026-E2030.
61. Meissner T, Otonkoski T, Feneberg R, et al. Exercise induced hy-poglycaemic hyperinsulinism. Arch Dis Child. 2001;84:254-257.
62. Otonkoski T, Kaminen N, Ustinov J, et al. Physical exercise-induced hyperinsulinemic hypoglycemia is an autosomal-dominant trait characterized by abnormal pyruvate-induced insulin release. Diabetes. 2003;52:199-204.
63. Otonkoski T, Jiao H, Kaminen-Ahola N, et al. Physical exercise-induced hypoglycemia caused by failed silencing of monocarboxy-late transporter 1 in pancreatic β cells. Am J Hum Genet. 2007;81: 467-474.
64. Otonkoski T, Meissner T. Exercise-induced hyperinsulinism: a failure of monocarboxylate transporter 1 expression silencing. In: Stanley CA, De León DD, eds. Monogenic Hyperinsulinemic Hypoglycemia Disorders. Geneva: Karger; 2012:172-181.
65. van Hasselt PM, Ferdinandusse S, Monroe GR, et al. Monocarboxylate transporter 1 deficiency and ketone utilization. N Engl J Med. 2014;371:1900-1907.
66. Quintens R, Hendrickx N, Lemaire K, Schuit F. Why expression of some genes is disallowed in β-cells. Biochem Soc Trans. 2008;36: 300-305.
67. Pinney SE, Ganapathy K, Bradfield J, et al. Dominant form of congenital hyperinsulinism maps to HK1 region on 10q. Horm Res Paediatr. 2013;80:18-27.
68. Tegtmeyer LC, Rust S, van Scherpenzeel M, et al. Multiple pheno-types in phosphoglucomutase 1 deficiency. N Engl J Med. 2014; 370:533-542.
69. Ackermann AM, Li C, Freeze HH, Ficicioglu C, Kaestner KH, Stanley CA. Hypoglycemia due to lower threshold of glucose-stimulated insulin secretion in phosphoglucomutase 1 deficiency. Platform Presentation at: Annual Meeting of the Pediatric Academic Societies, April 25-28, 2015; San Diego, CA.
70. Kalish JM, Boodhansingh KE, Bhatti TR, et al. Congenital hyperinsulinism in children with paternal 11p uniparental isodisomy and Beckwith-Wiedemann syndrome. J Med Genet. 2016;53:53-61.
71. Geneviève D, Amiel J, Viot G, et al. Atypical findings in Kabuki syndrome: report of 8 patients in a series of 20 and review of the literature. Am J Med Genet A. 2004;129A:64-68.
72. Alkhayyat H, Christesen HB, Steer J, Stewart H, Brusgaard K, Hus-sain K. Mosaic Turner syndrome and hyperinsulinaemic hypoglycaemia. J Pediatr Endocrinol Metab. 2006;19:1451-1457.
73. Gibson CE, Boodhansingh KE, Ganguly AE, Stanley CA. Congenital hyperinsulinism in Turner's syndrome. Poster LBS 024-030 presented at: 97th Annual Meeting of the Endocrine Society, March 5-8, 2015; San Diego, CA.
74. Kapoor RR, James C, Hussain K. Hyperinsulinism in developmental syndromes. Endocr Dev. 2009;14:95-113.
75. Lupsa BC, Chong AY, Cochran EK, Soos MA, Semple RK, Gorden P. Autoimmune forms of hypoglycemia. Medicine (Baltimore). 2009;88:141-153.
76. Redmon JB, Nuttall FQ. Autoimmune hypoglycemia. Endocrinol Metab Clin North Am. 1999;28:603-618, vii.
77. Alves C, Constança J, De León DD, Snider K, Stanley C. A novel atypical presentation of insulin autoimmune syndrome (Hirata's disease) in a child. J Pediatr Endocrinol Metab. 2013;26:1163-1166.
78. Takayama-Hasumi S, Eguchi Y, Sato A, Morita C, Hirata Y. Insulin autoimmune syndrome is the third leading cause of spontaneous hypoglycemic attacks in Japan. Diabetes Res Clin Pract. 1990;10: 211-214.
79. Arya VB, Flanagan SE, Schober E, Rami-Merhar B, Ellard S, Hussain K. Activating AKT2 mutation: hypoinsulinemic hypoketotic hypoglycemia. J Clin Endocrinol Metab. 2014;99:391-394.
80. Hussain K, Challis B, Rocha N, et al. An activating mutation of AKT2 and human hypoglycemia. Science. 2011;334:474.
81. Nellist M, Schot R, Hoogeveen-Westerveld M, et al. Germline activating AKT3 mutation associated with megalencephaly, polymi-crogyria, epilepsy and hypoglycemia. Mol Genet Metab. 2015;114: 467-473.
82. Højlund K, Hansen T, Lajer M, et al. A novel syndrome of autosomal-dominant hyperinsulinemic hypoglycemia linked to a mutation in the human insulin receptor gene. Diabetes. 2004;53:1592-1598.
83. Hoe FM, Thornton PS, Wanner LA, Steinkrauss L, Simmons RA, Stanley CA. Clinical features and insulin regulation in infants with a syndrome of prolonged neonatal hyperinsulinism. J Pediatr. 2006; 148:207-212.
84. Collins JE, Leonard JV. Hyperinsulinism in asphyxiated and small-for-dates infants with hypoglycaemia. Lancet. 1984;2:311-313.
85. Collins JE, Leonard JV, Teale D, et al. Hyperinsulinaemic hypoglycaemia in small for dates babies. Arch Dis Child. 1990;65:1118-1120.
86. Thornton PS, Stanley CA, De Leon DD, et al. Recommendations from the Pediatric Endocrine Society for evaluation and management of persistent hypoglycemia in neonates, infants, and children. J Pediatr. 2015;167:238-245.
87. Henquin JC, Sempoux C, Marchandise J, et al. Congenital hyperinsulinism caused by hexokinase I expression or glucokinase-acti-vating mutation in a subset of β-cells. Diabetes. 2013;62:1689-1696.
88. Le Quan Sang KH, Arnoux JB, Mamoune A, et al. Successful treatment of congenital hyperinsulinism with long-acting release octreotide. Eur J Endocrinol. 2012;166:333-339.
89. Calabria AC, Li C, Gallagher PR, Stanley CA, De León DD. GLP-1 receptor antagonist exendin-(9-39) elevates fasting blood glucose levels in congenital hyperinsulinism owing to inactivating mutations in the ATP-sensitive K+ channel. Diabetes. 2012; 61:2585-2591.
90. Senniappan S, Alexandrescu S, Tatevian N, et al. Sirolimus therapy in infants with severe hyperinsulinemic hypoglycemia. N Engl J Med. 2014;370:1131-1137.
91. Li C, Nissim I, Chen P, et al. Elimination of KATP channels in mouse islets results in elevated [U-13C]glucose metabolism, glutaminoly-sis, and pyruvate cycling but a decreased 7-aminobutyric acid shunt. J Biol Chem. 2008;283:17238-17249.
92. Kibbey RG, Pongratz RL, Romanelli AJ, Wollheim CB, Cline GW, Shulman GI. Mitochondrial GTP regulates glucose-stimulated insulin secretion. Cell Metab. 2007;5:253-264.
93. Li C, Liu C, Nissim I, et al. Regulation of glucagon secretion in normal and diabetic human islets by 7-hydroxybutyrate and glycine. J Biol Chem. 2013;288:3938-3951.
94. Kibbey RG, Choi CS, Lee HY, et al. Mitochondrial GTP insensitivity contributes to hypoglycemia in hyperinsulinemia hyperammonemia by inhibiting glucagon release. Diabetes. 2014;63: 4218-4229.
95. Kassem S, Bhandari S, Rodríguez-Bada P, et al. Large islets, β-cell proliferation, and a glucokinase mutation. N Engl J Med. 2010; 362:1348-1350.
96. Tornovsky-Babeay S, Dadon D, Ziv O, et al. Type 2 diabetes and congenital hyperinsulinism cause DNA double-strand breaks and p53 activity in β cells. Cell Metab. 2014;19:109-121.
97. Avrahami D, Li C, Yu M, et al. Targeting the cell cycle inhibitor p57Kip2 promotes adult human β cell replication. J Clin Invest. 2014;124:670-674.
98. Bhatti TR, Ganapathy K, Huppmann AR, et al. Histologic and molecular profile of pediatric insulinomas: evidence of a paternal par-ent-of-origin effect [published online January 12, 2016].J Clin Endocrinol Metab. doi:10.1210/jc.2015-2914.